# CK Regeon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ck-regeon

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.ckregeon.com
- Total disclosed funding: $18M
- Latest round: Series B (Feb 16, 2021)
- Investors on record: 7

## About

CK Regeon Inc. is a biotechnology firm focused on developing First-In-Class drugs with clear mechanisms of action, enhancing treatment options for various diseases, and improving the quality of human life.Founded in 2016, CK Regeon Inc. is headquartered in Seoul, South Korea. The company specializes in biotechnology solutions that aim to treat various diseases. The firm has successfully completed three funding deals, with the most recent being a Series B round in February 2021, raising KRW 13.5 billion. The funding was led by KNet Investment Partners, Korea Development Bank, SEOUL BIOHUB, Synergy IB Investment, and Yozma Group Korea. CEO Kang-Yell Choi leads the company, bringing experience from previous ventures.CK Regeon Inc. specializes in the development of First-In-Class drugs that demonstrate clear mechanisms of action (MOA). The company's core offerings are centered on innovative biotechnology solutions aimed at treating various diseases, enhancing the quality of human life. These products target healthcare providers and pharmaceutical companies, featuring advanced screening systems and a developmental platform for streamlined drug discovery. CK Regeon’s products are positioned to serve the North American and European markets, which have high demand for novel therapeutics with proven efficacy.CK Regeon Inc. generates revenue through strategic partnerships and collaborations within the biotechnology sector. The company engages in B2B transactions with research institutions and pharmaceutical companies, which leverage its proprietary technologies and drug development capabilities. Revenue streams include licensing agreements for flagship products and milestone payments from development agreements tied to performance criteria. CK Regeon may also explore subscription-based arrangements for ongoing access to its research and development services to facilitate consistent income from its technological innovations.In February 2021, CK Regeon Inc. raised KRW 13.5 billion in Series B funding to support upcoming clinical trials. The company plans to introduce new products designed to enhance its drug portfolio and will focus on expanding into additional markets in North America and Europe by 2023. The recent funding will be allocated to clinical research and trials aimed at accelerating product development and market entry.

## Funding rounds

- Series B, Feb 16, 2021, $12M — Korea Development Bank, KNet Investment Partners, Yozma Group Korea, Synergy IB Investment, SEOUL BIOHUB
- Series A, Apr 1, 2018, $5.6M — Korea Development Bank, Hyundai Venture Investment, Synergy IB Investment
- Seed, Feb 1, 2018 — Korea Tech Incubator for Startup, Synergy IB Investment

## Investors

- Korea Tech Incubator for Startup — Seed
- Synergy IB Investment (https://capitalatlas.ai/funds/synergy-ib-investment) — Seed, Series A, Series B
- Korea Development Bank (https://capitalatlas.ai/funds/korea-development-bank) — Series A, Series B
- Hyundai Venture Investment (https://capitalatlas.ai/funds/hyundai-venture-investment) — Series A
- KNet Investment Partners (https://capitalatlas.ai/funds/knet-investment-partners) — Series B
- Yozma Group Korea (https://capitalatlas.ai/funds/yozma-group-korea) — Series B
- SEOUL BIOHUB — Series B